Results 201 to 210 of about 206,195 (300)

Comment on: “Impact of Depth of Invasion in Node‐Negative Oral Tongue Cancer Treated With Surgery Alone”

open access: yes
The Kaohsiung Journal of Medical Sciences, EarlyView.
Erkan Topkan, Efsun Somay, Ugur Selek
wiley   +1 more source

A National Analysis of Microscopic Positive Margins in Oropharyngeal Cancer Patients Undergoing Transoral Robotic Surgery

open access: yesOtolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective The objective was to identify clinical variables associated with microscopic positive margins (PMs) during transoral robotic surgery (TORS) for oropharyngeal cancer (OPC) resection, and to explore the association of the receipt of adjuvant treatment with overall survival (OS) in this population.
Aaron Tucker, Craig A. Bollig
wiley   +1 more source

Outcomes and Risk Factors in Oncologic Temporal Bone Surgery: A Head and Neck‐Specific NSQIP Analysis

open access: yesOtolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective Advanced temporal bone and parotid gland malignancies are rare and difficult to manage. However, complications of oncologic temporal bone surgery have not been systematically categorized. We aim to detail the postoperative outcomes of lateral temporal bone resection (LTBR) and mastoidectomy for otologic oncology patients, and ...
Bailey H. Duhon   +5 more
wiley   +1 more source

Does Smoking Influence Outcomes in Human Papillomavirus—Associated Oropharyngeal Cancer Treated with Transoral Robotic Surgery?

open access: yesOtolaryngology–Head and Neck Surgery, EarlyView.
Abstract Objective Smoking has been identified as a risk factor for recurrence in HPV‐associated oropharyngeal squamous cell carcinoma (OPSCC) treated with definitive chemoradiation. Whether the same prognostic significance holds with surgical treatment such as transoral robotic surgery (TORS) is less well studied.
Jane Y. Tong   +8 more
wiley   +1 more source

Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial. [PDF]

open access: yesCurr Oncol
Yamashita G   +19 more
europepmc   +1 more source

A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 460-473, March 2025.
Abstract In oncology drug development, measuring drug concentrations at the tumor site and at the targeted receptor remains an ongoing challenge. Positron emission tomography (PET)‐imaging is a promising noninvasive method to quantify intratumor exposure of a radiolabeled drug (biodistribution data) and target saturation by treatment doses in vivo ...
Robin Michelet   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy